Indeed, FGFR1 is frequently amplified or mutated in prostate adenocarcinoma (23%), lung squamous carcinoma (23%) and breast cancer (14.3%) (TCGA), and FGFR inhibitors are being trialled clinically. Here, FGFR1 is linked to breast carcinoma.